241 related articles for article (PubMed ID: 26775917)
21. [Advances on treatment of pediatric acute lymphoblastic leukemia with blinatumomab].
Wang D; Zhao C; Xu XJ
Zhonghua Er Ke Za Zhi; 2024 May; 62(5):482-485. PubMed ID: 38623020
[TBL] [Abstract][Full Text] [Related]
22. Blinatumomab for Acute Lymphoblastic Leukemia.
Mori J; Oshima K; Tanimoto T
N Engl J Med; 2017 Jun; 376(23):e49. PubMed ID: 28594155
[No Abstract] [Full Text] [Related]
23. Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab.
Lau KM; Saunders IM; Goodman AM
J Oncol Pharm Pract; 2021 Jun; 27(4):821-826. PubMed ID: 32605497
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Chang J; Shen YJ; Shi T; Wang HF; Jin J; Zhu HH
Ann Hematol; 2023 May; 102(5):1275-1277. PubMed ID: 36892592
[No Abstract] [Full Text] [Related]
25. Application of Medicare's New Technology Add-on Payment Program for Blinatumomab.
Dhruva SS; Prasad V
JAMA Oncol; 2016 Feb; 2(2):165-6. PubMed ID: 26720844
[No Abstract] [Full Text] [Related]
26. Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma.
Ivanov V; Farnault L; Mercier C; Colavolpe C; Venton G; Colle J; Lepidi H; Arnoux I; Nicolino-Brunet C; Berda-Haddad Y; Fanciullino R; Ivanov G; Costello R
Leuk Lymphoma; 2020 May; 61(5):1230-1233. PubMed ID: 31900013
[No Abstract] [Full Text] [Related]
27. Comment on: Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Srinivasan S; Roy Moulik N; Dhamne C
Pediatr Blood Cancer; 2023 Jan; 70(1):e29874. PubMed ID: 35735751
[No Abstract] [Full Text] [Related]
28. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Leoni V; Biondi A
Haematologica; 2015 Mar; 100(3):295-9. PubMed ID: 25740105
[No Abstract] [Full Text] [Related]
29. A review of blinatumomab, a novel immunotherapy.
Newman MJ; Benani DJ
J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
[TBL] [Abstract][Full Text] [Related]
30. A balancing act: Blinatumomab use in a rare occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in an adolescent patient with Down syndrome.
Rav ES; Wahba A; Patnaik A; Toruner G; Hittle A; Toepfer L; Roth M; Cuglievan B; Nunez C; McCall D
Pediatr Blood Cancer; 2023 May; 70(5):e30191. PubMed ID: 36602024
[No Abstract] [Full Text] [Related]
31. Isolated salivary gland extramedullary relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment.
Kawakami Y; Imamura M; Imai C
Int J Hematol; 2024 May; 119(5):479-480. PubMed ID: 38492197
[No Abstract] [Full Text] [Related]
32. Reasons for optimism in the therapy of acute leukemia.
Rowe JM
Best Pract Res Clin Haematol; 2015; 28(2-3):69-72. PubMed ID: 26590761
[TBL] [Abstract][Full Text] [Related]
33. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.
Rayes A; McMasters RL; O'Brien MM
Pediatr Blood Cancer; 2016 Jun; 63(6):1113-5. PubMed ID: 26914337
[TBL] [Abstract][Full Text] [Related]
34. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia.
Handgretinger R; Zugmaier G; Henze G; Kreyenberg H; Lang P; von Stackelberg A
Leukemia; 2011 Jan; 25(1):181-4. PubMed ID: 20944674
[No Abstract] [Full Text] [Related]
35. Delayed-onset severe neurotoxicity related to blinatumomab in an adolescent patient with refractory acute lymphoblastic leukemia.
Filippidou M; Avgerinou G; Katsibardi K; Gavra M; Pons R; Kattamis A
Pediatr Blood Cancer; 2021 Jul; 68(7):e29040. PubMed ID: 33788389
[No Abstract] [Full Text] [Related]
36. Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data.
Vakharia P; Nardone B; Budris W; Hoshizaki K; Frankfurt O; West DP
Leuk Lymphoma; 2018 Jul; 59(7):1759-1761. PubMed ID: 29115884
[No Abstract] [Full Text] [Related]
37. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
Algeri M; Del Bufalo F; Galaverna F; Locatelli F
Expert Rev Hematol; 2018 Dec; 11(12):945-956. PubMed ID: 30358451
[TBL] [Abstract][Full Text] [Related]
38. Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission.
Hilal T; Prasad V
Nat Rev Clin Oncol; 2018 Dec; 15(12):727-728. PubMed ID: 30181661
[No Abstract] [Full Text] [Related]
39. Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.
Marini BL; Sun Y; Burke PW; Perissinotti AJ
J Oncol Pharm Pract; 2018 Jan; 24(1):67-73. PubMed ID: 27799606
[TBL] [Abstract][Full Text] [Related]
40. Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.
Keating AK; Gossai N; Phillips CL; Maloney K; Campbell K; Doan A; Bhojwani D; Burke MJ; Verneris MR
Blood Adv; 2019 Jul; 3(13):1926-1929. PubMed ID: 31243002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
